T-cell engagers, especially BiTEs, show promise in treating solid tumors by targeting tumor-associated antigens and redirecting T-cell activity. Tarlatamab, targeting DLL3 in SCLC, demonstrated ...
Preclinical data support Abalos’ first-in-class approach of safely harnessing the immunostimulatory and anti-tumoral properties of arenaviruses to treat solid tumors -- Düsseldorf, Germany, October 14 ...
Samer A. Srour, MB ChB, MS, has long hoped the remarkable success of chimeric antigen receptor therapy for treatment of hematologic malignancies could be replicated in other cancer types.“There is a ...
Zeaxanthin, best known for eye health, has been found to boost the tumor-killing power of T cells. Researchers showed it ...
The ZUMA-24 study showed outpatient axicabtagene ciloleucel (axi-cel) for DLBCL reduced hospitalization and improved safety profiles. CAR T-cell therapy for DLBCL shows promise in outpatient settings, ...
Sana Biotechnology, Inc. is a Strong Buy with promising cell therapies for diabetes & B-cell disorders. Click here to find ...
News-Medical.Net on MSN
Engineered CAR T cells show promise against solid tumors
T cell therapy, which uses a patient's own immune cells to fight cancer, has emerged as a powerful way to treat lymphoma and other blood cancers.
CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical ...
New research shows lymph nodes aren’t just cancer bystanders, they’re the command centers fueling immune attacks. Surgically removing them along with tumors may weaken treatment, while preserving them ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback